Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesH1N1 Vaccine Clinical Trials in Adults Free of Serious Adverse Events. Efficacy Data From Initial Doses Expected in September
American Family Physician, 08/28/09
Mitchell D – No serious adverse events have been reported during the first two weeks of clinical trials involving vaccine against the novel influenza A (H1N1) virus. Although there have been incidences of swelling and pain at the injection site, which is seen with almost every vaccine, there have been no serious adverse events. Clinical trials with adults and the elderly started Aug. 7 and are examining whether the vaccine should contain 15 mg or 30 mg of antigen, as well as whether one or two doses would be needed to provide adequate protection. The clinical trials also will determine whether the new vaccine should be given before, after or at the same time as seasonal flu vaccine. Data derived from participants who have received the first dose is expected to be available in mid–September, with second–dose data available in mid–October. On Aug. 19 and 20, similar trials began in children ages 6 months to 17 years. First–dose data from those trials should be available by late September, with second–dose data expected in late October. Trials involving pregnant women are scheduled to begin in early September, and trials involving the use of adjuvants are expected to start in mid– or late September.
Related Articles
Pandemic 2009 Influenza Update: Results from second clinical trial of GSKs H1N1 adjuvanted vaccine confirm immune response and tolerability
GlaxoSmithKline, 10/19/09
Relevance Score: 90%
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Youth Ages 10 to 17. Younger Children Likely Will Need Two Doses
American Family Physician, 10/05/09
Relevance Score: 90%
Sanofi Pasteur announces results of U.S. clinical trials in adults following one dose of influenza A (H1N1) vaccine
Sanofi-aventis, 10/02/09
Relevance Score: 90%
Pandemic 2009 Influenza Update: Pandemrix data on co-administration with annual seasonal influenza vaccine
GlaxoSmithKline, 11/10/09
Relevance Score: 89%
Interim Clinical Trial Results Show MedImmunes H1N1 Vaccine Has Similar Safety Profile as Seasonal Vaccine in Eligible Children and Adults
Medimmune, 10/23/09
Relevance Score: 89%
Today in Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment approaches to prosthetic joint infections: results of an Emerging Infections Network survey
Diagnostic Microbiology and Infectious Disease, 12/10/09
Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources
Tropical Medicine & International Health, 12/10/09
Copy-Years Viremia as a Measure of Cumulative Human Immunodeficiency Virus Viral Burden
American Journal of Epidemiology, 12/10/09
Today in Preventive Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Mediterranean diet and cognitive function in older adults
Current Opinion in Clinical Nutrition & Metabolic Care, 12/10/09
Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study
American Journal of Clinical Nutrition, 12/10/09
The Enhancing Secondary Prevention in Coronary Artery Disease trial
Canadian Medical Association Journal, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor